Register
Community
Overview
Experts
Editors
Fellows
Code of conduct
Company
About Us
FAQs
Privacy Policy
Terms of Use
Careers
Programs
News
News Releases
Press Coverage
Publications
Blog
Contact Us
Sign in
Please select the option that best describes you:
Topics:
Breast Cancer
•
Medical Oncology
•
Breast Cancer, Non-metastatic
Would you give adjuvant chemotherapy to a premenopausal female who underwent bilateral mastectomies for ER+ pT2N1 disease, grade 1, with low oncotype (5)?
How would you approach management in setting of CHEK2 mutation?
Related Questions
What would be your treatment approach in a premenopausal BRCA2+ patient with cT2N0 grade 2-3, ER negative, PR variably positive (30%; staining weak to high), HER2 negative breast cancer?
What is your treatment approach in a patient with cT2 ER+HER2+ breast cancer who refuses neoadjuvant chemotherapy?
Do you recommend self-breast exams to your patients with history of breast cancer in addition to imaging surveillance?
Is it safe to use hormone replacement therapy in young premenopausal patients with BRCA1 mutation, triple negative breast cancer, who have undergone bilateral mastectomies and BSO without hysterectomy?
What factors would you consider when deciding between tamoxifen vs OFS/AI in premenopausal women with early stage HR+ breast cancer?
What is the appropriate approach to manage a patient with triple-negative, locally advanced breast cancer (LN+) who progresses on neoadjuvant chemo-immunotherapy (KEYNOTE-522 regimen)?
Do you hold endocrine therapy during adjuvant breast radiotherapy?
Would you send Oncotype for pre-menopausal women with HR+, HER2(-) breast cancer with a small tumor (pT1b) and micrometastatic LN involvement or recommend adjuvant chemotherapy without sending Oncotype?
Do you routinely check hormone levels to confirm postmenopausal status before adding aromatase inhibitors to lupron in premenopausal women with early breast cancer?
Would you offer adjuvant endocrine therapy to a male with ER+ DCIS?